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Objective: Recent evidence suggests the substantial pathogenic role of the Janus kinase (JAK)/signal transducer and activator of transcription
(STAT) pathway in the development of low-grade chronic inflammatory response, known as “metaflammation,” which contributes to obesity and
type 2 diabetes. In this study, we investigated the effects of the JAK1/2 inhibitor baricitinib, recently approved for the treatment of rheumatoid
arthritis, in a murine high-fat-high sugar diet model.
Methods: Male C57BL/6 mice were fed with a control normal diet (ND) or a high-fat-high sugar diet (HD) for 22 weeks. A sub-group of HD fed
mice was treated with baricitinib (10 mg/kg die, p.o.) for the last 16 weeks (HD þ Bar).
Results: HD feeding resulted in obesity, insulin-resistance, hypercholesterolemia and alterations in gut microbial composition. The metabolic
abnormalities were dramatically reduced by chronic baricitinib administration. Treatment of HD mice with baricitinib did not change the diet-
induced alterations in the gut, but restored insulin signaling in the liver and skeletal muscle, resulting in improvements of diet-induced myo-
steatosis, mesangial expansion and associated proteinuria. The skeletal muscle and renal protection were due to inhibition of the local JAK2-
STAT2 pathway by baricitinib. We also demonstrated that restored tissue levels of JAK2-STAT2 activity were associated with a significant
reduction in cytokine levels in the blood.
Conclusions: In summary, our data suggest that the JAK2-STAT2 pathway may represent a novel candidate for the treatment of diet-related
metabolic derangements, with the potential for EMA- and FDA-approved JAK inhibitors to be repurposed for the treatment of type 2 diabetes and/
or its complications.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Low-grade, chronic inflammatory response, known as “meta-
flammation,” exerts a key role in promoting diet-related metabolic
disorders [1]. Several studies have provided clear evidence of a
causative relationship between exposure to hypercaloric diets and
quantitative and qualitative changes in intestinal commensal bacteria
communities, which can, in turn, lead to metabolic endotoxemia and
the over-production of inflammatory mediators, which drive the
development of dysglycemic and dyslipidemic states [2]. Treatments
that halt or induce regression of metaflammation have the potential to
provide immense clinical, social and economic benefits. However, only1Department of Drug Science and Technology, University of Turin, Turin, Italy 2Queen M
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flammatory pathways activated by the metabolic, biochemical and
hemodynamic derangements known to exist in metabolic diseases.
The Janus kinase (JAK) signal transducer and activator of transcription
(STAT) pathway has recently been described as a potential master
regulator of signaling events, regulating more than 50 cytokine or
hormone receptors, many of which play pivotal roles in the patho-
physiology of metaflammation [3,4]. JAK1, JAK2, JAK3 and tyrosine
kinase 2 (TYK2) are different isoforms of the mammalian JAK family
[5]. They can be selectively activated by different receptors, leading to
specific or relatively discrete functional outcomes. JAK signaling has
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Original Articleobesity and type 2 diabetes mellitus (T2DM) [6]. Studies of knock-out
mice confirmed the pivotal role of JAK signaling, mainly JAK2, in the
regulation of a multitude of metabolic processes including, but not
limited to, glucose tolerance, insulin sensitivity, leptin sensitivity, en-
ergy expenditure and adiposity. Clinically suitable STAT inhibitors are
not yet available, whereas small molecule inhibitors of the upstream
JAK proteins have been recently developed and are now approved for
several chronic inflammatory disorders including rheumatoid arthritis,
ulcerative colitis, myelofibrosis and polycythemia. The efficacy of these
drugs is thought to be due to reduced T and B cell activation [7] and
therefore a reduction in the inflammation that drives the progression of
the disease itself [8,9]. However, to the best of our knowledge, the
effects of the pharmacological modulation of JAK signaling in the
clinical context of insulin resistance and diet-related metabolic disor-
ders have been poorly investigated. A recently published study on rats
with streptozotocin-induced diabetes investigated the effects of the
pharmacological inhibition of JAK signaling. The authors demonstrated
that combination therapy of tofacitinib (10 mg/kg BW) and aspirin
(100 mg/kg BW) in rats significantly improved glucose homeostasis
and insulin secretion compared to diabetic (untreated) rats [10].
Tofacitinib is a JAK3 inhibitor. Other authors have convincingly
demonstrated that loss of JAK3 in mice results in body weight gain,
impaired glycemic and lipid homeostasis and early symptoms of liver
steatosis [11]. In contrast, JAK2 deficiency in the liver, macrophages,
or adipocytes protects against high-fat diet induced metabolic
inflammation [12e14], suggesting that JAK2 may be a promising
target for the treatment of obesity, metabolic syndrome and T2DM. The
JAK1/2 inhibitor baricitinib was approved in February 2017 for the
treatment of moderate to severe active rheumatoid arthritis. Baricitinib
shows a selective and balanced potency against JAK1 (IC50 5.9 nM)
and JAK2 (IC50 5.7 nM) with far less potency for JAK3 (IC50> 400 nM),
thus being considered a JAK3 sparing agent. In a recently concluded
phase 2, double-blind, dose-ranging study in patients with T2DM and
diabetic kidney disease, baricitinib was demonstrated to decrease
inflammatory biomarkers over 24 weeks and this effect was associ-
ated with a significant reduction in albuminuria [15]. In this study, we
investigated the effects of the pharmacological modulation of the JAK
cascade with baricitinib in an in vivo model of diet-induced metabolic
alterations to evaluate the efficacy and mechanism of action of bar-
icitinib to provide “proof of concept” evidence for the repurposing of
JAK inhibitors in metabolic diseases.
2. MATERIALS AND METHODS
2.1. Animals and experimental procedures
The in vivo experimental procedures described herein were approved
by the local Animal Use and Care Committee and the Ministry of
Health (approval no. 42/2017-PR) in keeping with the European
Directive 2010/63/EU on the protection of animals used for scientific
purposes as well as the Guide for the Care and Use of Laboratory
Animals. This study was conducted using 4-week-old male C57BL/6
mice maintained in conventional housing conditions in a controlled
environment at 25  2 C. The mice were co-housed one week prior
to the onset of the experiments and randomly allocated to three
experimental groups (n ¼ 15 per group): mice fed a control normal
diet (ND group), mice fed a high-fat and high-sugar diet (45 kJ% fat,
35 kJ% sugar) for 22 weeks (HD group), and mice fed an HD for 22
weeks and treated with baricitinib (10 mg/kg die, p.o.) for the last 16
weeks (HD þ Bar). The dietary protocol chosen was based on those
used in previous animal studies showing that similar compositions
and kinetics of dietary manipulation resulted in robust changes in2 MOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier Glipid and glucose profiles as well as body weight gain [16e18]. Body
weight and food/water intake were recorded weekly, whereas fasting
glucose was recorded monthly. Urine and feces samples were
collected at weeks 0, 5 and 22 (18 h metabolic cages). Total urinary
protein and urine albumin concentrations were compared with
creatinine concentrations to calculate the albumin to creatinine ratio
(ACR) as an indicator of albuminuria. Baricitinib was administered as
an added dietary component. The chronic administration of the
baricitinib dose used in this study did not lead to adverse effects [19]
and has been shown to reduce the contribution of Th1 cells to
metaflammation in obese mice [20].
2.2. Oral glucose tolerance test (OGTT)
One day before the end of the experiment, an OGTT was conducted
after an overnight fasting period. Glucose (2 g/kg) was administered by
oral gavage and blood was obtained from the saphenous vein once
before the glucose administration and after 15, 30, 60 and 120 min.
The glucose concentration was measured with a conventional gluc-
ometer (GlucoMen LX kit, Menarini Diagnostics, Grassina, Italy).
2.2.1. MRI
The mice were anesthetized using 5% isoflurane and placed on a bed
with water heated to 50 C passing through it to maintain body
temperature. Respiration was monitored using a pressure sensor
placed under the abdomen. The mice were imaged in a Brucker ICON
1T preclinical MRI scanner using a body coil and a T2 weighted RARE
3D isotropic image with TR of 1500 ms and TE of 84 ms and a voxel
size of 0.219 X 0.375  0.375 mm. Images were analyzed using
VivoQuant software (Invicro LLC, Boston, MA, USA). 3D regions of in-
terest (ROI) were used to isolate the quadriceps muscle of a randomly
selected mouse. Within the ROI, a threshold was set for all of the pixels
appearing to contain fat and the pixel volume was quantified by the
software. The results for both of these volumes are presented as a
percentage of the total quad area exceeding the fat threshold.
2.3. Biochemical analysis
After 22 weeks of dietary manipulation, the mice (fasted for 4 h) were
anesthetized using isoflurane (IsoFlo, Abbott Laboratories) and killed by
cardiac exsanguination. Blood samples were collected and the plasma
was isolated. Plasmatic concentrations of triglycerides (TGs), total
cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein
(LDL) were measured using reagent kits according to standard enzy-
matic procedures (Hospitex Diagnostics, Florence, Italy). Plasma in-
sulin, leptin, ghrelin, glucose-dependent insulinotropic polypeptide
(GIP), glucagon-like peptide (GLP-1), resistin, IL-1b, TNF-a, IFN-ɣ, IL-6
and IL-10 levels were measured using a Luminex suspension bead-
based multiplexed Bio-Plex 3D system (Bio-Rad Laboratories, Hercu-
les, CA, USA).
2.4. Fecal microbiota analysis
Total genomic DNA extraction from frozen feces was conducted using
a QIAamp PowerFecal DNA Isolation kit (MO BIO Laboratories, Inc.,
Carlsbad, CA, USA) and then subjected to PCR amplification by tar-
geting 16S rRNA V3eV4 variable regions with specific bacterial primer
set 341F (50-CCTACGGGNGGCWGCAG-30) and 806R (50-GAC-
TACNVGGGTWTCTAATCC-30) as previously reported [21]. PCR products
were assessed via gel electrophoresis and cleaned using an Agencourt
AMPure XP system (Beckman Coulter, Brea, CA, USA) following the
manufacturer’s instructions. After 7 PCR cycles (16S Metagenomic
Sequencing Library Preparation, Illumina), Illumina adaptors were
attached (Illumina Nextera XT Index Primer). Libraries were purifiedmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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using Agencourt AMPure XP (Beckman) and then sequenced on an
Illumina MiSeq (PE300) platform (MiSeq Control software 2.0.5 and
Real-Time Analysis software 1.16.18). Sequences obtained from Illu-
mina sequencing were analyzed using the Quantitative Insights Into
Microbial Ecology (QIIME) 2.0 pipeline [22]. The percentage relative
abundance of taxa from different dietary groups were compared using
the non-parametric Wilcoxon statistical test.
2.5. Tissue extracts
Liver, skeletal muscle and kidney extracts were prepared as previously
described [23]. Briefly, tissues were homogenized and centrifuged at
10,000  g for 20 min at 4 C. Supernatants were collected and the
protein content was determined using a BCA protein assay (Pierce
Biotechnology Inc., Rockford, IL, USA) following the manufacturer’s
instructions.
2.6. Skeletal muscle TG level
TGs were extracted from the total tissue homogenates of the skeletal
muscle and assayed using a triglyceride quantification kit (Abnova
Corporation, Aachen, Germany).
2.7. Western blotting analysis
Proteins were separated by 8% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
polyvinyldenedifluoride (PVDF) membrane, which was then incubated
with primary antibodies (dilution 1:1000). The antibodies used were
rabbit anti-Tyr1007/1008 JAK2 (#3776), rabbit anti-total JAK2 (#3230),
rabbit anti-Tyr690 STAT2 (Bioss Antibodies, bs-3428R), rabbit anti-total
STAT2 (#72604), rabbit p21 (#2947), rabbit anti-Ser307 IRS-1 (#2381),
mouse anti-total IRS-1 (#3194), rabbit anti-Ser473 AKT (#4060), rabbit
anti-total AKT (#9272), rabbit anti-Ser9 GSK-3b (#9332) and rabbit
anti-total GSK-3b (9315).
The blots were then incubated with secondary antibodies conjugated
with horseradish peroxidase (dilution 1:20000) and developed using an
ECL detection system. Bio-Rad Image Lab Software 6.0.1 was used to
analyze the immunoreactive bands and the results were normalized to
the controls.
2.8. Kidney histopathological examination
Histology was conducted on formalin-fixed paraffin-embedded (FFPE)
samples that were subsequently stained with either hematoxylin and
eosin (H&E stain) or periodic acid Schiff stain (PAS) before being
visualized using a NanoZoomer digital pathology scanner (Hamamatsu
Photonics K.K., Hamamatsu City, Japan). The samples were then
analyzed using a NanoZoomer NDP viewer software (Hamamatsu
Photonics K.K., Japan). Two cross-sectional measurements (at 90 to
one another) were obtained for 10 renal corpuscles and glomeruli and
averaged before an area for each was established using the formula
A ¼ pr2.
2.9. Materials
Unless otherwise stated, all of the compounds were purchased from
SigmaeAldrich Ltd. (St. Louis, MO, USA). The BCA Protein Assay kit
was obtained from Pierce Biotechnology Inc. (Rockford, IL, USA).
Antibodies were purchased from Cell-Signaling Technology (Beverly,
MA, USA).
2.10. Statistical analysis
All of the values in the text and figures are expressed as
mean  S.E.M. for n observations. The data distribution were verified
by the ShapiroeWilk normality test and the homogeneity of variancesMOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier GmbH. This is
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way ANOVA followed by the NewmaneKeuls post hoc test. Data that
were not normally distributed were analyzed with the KruskaleWallis
test followed by Dunn’s test. OGTTs were analyzed using the area
under the receiver operating characteristic (ROC) curve. A p
value < 0.05 was considered statistically significant. Statistical
analysis was conducted using GraphPad Prism 5.03 (GraphPad Soft-
ware, San Diego, CA, USA).
3. RESULTS
3.1. Effects of dietary manipulation and baricitinib administration
on metabolic parameters and gut microbiota composition
When compared to the ND fed mice, the mice fed an HD had elevated
plasma levels of insulin, leptin,and resistin (Figure 1AeC) associated
with decreased plasma levels of ghrelin, GIP and GLP-1 (Figure 1DeF).
Treatment of the mice fed a hypercaloric diet with baricitinib
(HD þ Bar) restored these master hormonal regulators of metabolism
back to values similar to those seen in the control mice, but the effect
of baricitinib on GLP-1 was not significant. Although no significant
differences in food intake (g/die) among any of the experimental
groups were recorded, the mice exposed to the hypercaloric diet
showed a significant increase in daily caloric intake (14.83  1.63
kcal/die) compared to the mice fed the normocaloric diet (8.30 0.18
kcal/die), resulting in weight gain (Figure 2A), higher blood glucose
levels (Figure 2B), and OGTT impairment (Figure 2C,D). The diet
changes in the body weight and blood glucose levels were significantly
reduced in the HD fed mice treated with baricitinib, which did not
significantly affect either food or calorie intake.
No differences were observed in the composition of the microbiota at
T0 (baseline) among any of the groups studied. The HD and HD þ Bar
mice significantly differed from the ND mice in fecal microbial b di-
versity at T11 (not shown) and T22 weeks (Figure 3A), but not in a
diversity (not shown). At the phylum level, the ND mice had higher
Bacteroidetes/Firmicutes ratios at T22 than the HD (p ¼ 0.001) and
HDþ Bar (p¼ 0.0008) mice. Both the HD and HDþ Bar mice differed
from the ND mice for decreased Bacteroides (p¼ 0.027 and p¼ 0.04,
respectively), Ruminococcus (p < 0.001 and p ¼ 0.003, respectively),
Anaerostipes (p < 0.001 and p ¼ 0.001, respectively), Anaeroplasma
(p < 0.001 and p ¼ 0.001, respectively), and Muribaculaceae family
(p < 0.001 and p ¼ 0.001, respectively) and increased Dehalo-
bacterium (p ¼ 0.018; p ¼ 0.05, respectively), Lachnospira
(p < 0.001 and p ¼ 0.005, respectively), Dorea (p < 0.001 and
p ¼ 0.003, respectively), Oscillospira (p ¼ 0.002 and p ¼ 0.003,
respectively), Streptococcus (p < 0.001 and p ¼ 0.004, respectively),
Lawsonia (p < 0.001 and p ¼ 0.003, respectively), and Lachnospir-
aceae family (p < 0.001 and p ¼ 0.002, respectively), indicative of
high-sugar, high-fat, and diet-induced microbiota imbalances
(Figure 3B,C). Moreover, the HD mice treated with baricitinib also
differed from the ND mice for decreased Prevotella (p ¼ 0.002).
3.2. Baricitinib ameliorates local insulin signal transduction
affected by HD
Chronic exposure to HD was associated with a robust increase in
Ser307 phosphorylation of insulin receptor substrate-1 (IRS-1) in liver
(Figure 4A) and skeletal muscle (Figure 4B) compared to ND feeding.
These effects were associated with a robust hepatic and skeletal
muscle decrease in Ser473 phosphorylation of protein kinase B (AKT)
(Figure 4C,D) and Ser9 phosphorylation of glycogen synthase kinase-
3b (GSK-3b) (Figure 4E,F), two of the main downstream mediators of
the insulin signaling pathway. These alterations in proteinan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Figure 1: Plasma concentrations of: insulin (A), leptin (B), resistin (C), ghrelin (D); GIP (E), and GLP-1 (F). All of the data are expressed as mean  SEM for n ¼ 15 per group.
*p<0.05 vs ND and p<0.05 vs HD.
Original Articlephosphorylation were suggestive of changes in the activation status of
the respective proteins, thus indicating that HD led to impairments in
insulin signaling. Interestingly, treatment of the HD mice with bar-
icitinib counteracted the changes in insulin signaling evoked by HD,
highlighting the drug’s ability to counteract diet-induced impairments
in the insulin signal transduction pathway.
3.3. Baricitinib attenuates dyslipidemia and myosteatosis
The mice exposed to HD showed marked increases in their plasma
serum triglyceride levels (1.07  0.02 mmol/L) and total cholesterol
(3.43  0.07 mmol/L) and LDL/HDL ratios (0.43  0.03) compared to
the control mice (0.87  0.03, 2.77  0.07, and 0.32  0.04,
respectively). The diet-induced changes in the plasma lipid profiles
were attenuated by treatment of the HD mice with baricitinib
(0.98  0.03, 2.89  0.03, and 0.32  0.02, respectively). The
systemic alterations in the lipid profiles evoked by HD were associated
with a significant deposition of fat within the skeletal muscle as shown4 MOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier Gby MRI analysis of the quadriceps muscle and confirmed by a two-fold
increase in the skeletal muscle triglyceride levels. In contrast, treat-
ment of the HD mice with baricitinib significantly attenuated the in-
crease in fat deposition and triglyceride content in the skeletal muscle
(Figure 5).
3.4. Baricitinib attenuates the HD-induced renal damage
As shown in Figure 6, the mice fed an HD showed a significant in-
crease in their urinary albumin creatinine ratio (ACR) in comparison to
mice fed ND, indicating the development of proteinuria, which was
reduced by baricitinib administration (Figure 6I). As proteinuria is often
associated with dilatations of Bowman’s capsule and glomerular hy-
pertrophy, we conducted a histological analysis of the kidneys obtained
from all of the animals (Figure 6AeF). The average size of the
glomeruli in the HD mice was larger than in the ND mice, indicating
glomerular hypertrophy (Figure 6H). This effect was associated with an
increase in the renal corpuscle area (Figure 6G). In contrast, treatmentmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Effects of diet and baricitinib on mouse body weight (A), basal non-fasted blood glucose and oral glucose tolerance at 22 weeks (B and C). Panel D shows the area under
curve (AUC) of the oral glucose tolerance test calculated for respective groups (n ¼ 6 per group) and used for statistical analysis (D). All of the data are expressed as mean  SEM
for n number of observations. *p<0.05 vs ND and p<0.05 vs HD.of the mice fed an HD with baricitinib abolished the glomerular hy-
pertrophy and increased Bowman’s space. A profound increase in
periodic acid-Schiff positive staining within the glomeruli (an indicator
of mesangial expansion) was recorded in the kidneys of the HD mice
compared to the ND mice (Figure 6A,B). In contrast, treatment of the
HD mice with baricitinib abolished the increase in mesangial expansion
(Figure 6C). A marker of mesangial expansion that has been demon-
strated to be increased in different types of glomerular diseases is the
cell cycle activator p21 (cyclin-dependent kinase inhibitor), the upre-
gulation of which is a direct consequence of the activation of the JAK-
STAT pathway [24]. Compared to the mice fed a normal chow diet, the
mice fed an HD showed a significant increase in the p21 levels in the
kidneys (Figure 6L), suggesting an early stage of diabetic nephropathy.
This increase in p21 was largely attenuated in the mice fed an HD and
treated with baricitinib.
3.5. Baricitinib reduces local JAK2 activity and systemic
inflammatory response
As shown in Figure 7 the skeletal muscle and kidney tissues of the
mice fed an HD exhibited a significant increase in the phosphorylation
of Tyr1007/1008 on JAK2 (Figure 7AeB), suggesting increased activation
resulting in a downstream increase in Tyr690 phosphorylation of STAT2
(Figure 7CeD), demonstrating that the JAK2-STAT2 signaling pathway
was activated in the skeletal muscle and kidneys of the mice that
demonstrated metabolic derangement. Taken together, these results
show that diet-induced increase in tissue dysfunction and injury are
associated with over-activation of the pro-inflammatory JAK2-STAT2
pathway. In contrast, the mice fed an HD and treated with baricitinib
had significantly reduced activation of JAK2 and downstream effector
STAT2, confirming baricitinib’s ability to interfere with its pharmaco-
logical target in our experimental conditions. The local over-activation
of JAK2-STAT2 was paralleled by increased plasma levels of the pro-
inflammatory mediators IL-1b, TNFa, and IFN-g as well as reducedMOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comlevels of anti inflammatory mediators IL-6 and IL-10 (Figure 8).
Interestingly, the systemic levels of pro-inflammatory cytokines that
signaled through the JAK-STAT pathway, such as IL-1b, TNFa, and
IFN-g [25e27], were reduced in the plasma of the HD mice exposed to
baricitinib. Baricitinib administration was simultaneously associated
with increased blood concentrations of IL-6 and IL-10, suggesting that
local inhibition of JAK2-STAT2 contributes to reducing the severity of
systemic metaflammation.
4. DISCUSSION
Unhealthy dietary habits along with sedentary behavior trigger a
multitude of pathophysiological changes evoking chronic metabolic
inflammation (called metaflammation), ultimately leading to the
development of obesity and insulin resistance [28]. In this study, we
confirmed that the mice exposed to HD for 22 weeks showed an
excessive production of pro-inflammatory cytokines accompanied by
the development of the expected dysmetabolic phenotype with
increased body weight, adiposity and elevated circulating insulin,
glucose and lipid levels. We also demonstrated that the hypercaloric
diet reshaped the gut microbial composition, inducing an obese
microbiota phenotype, depleting Bacteroidetes (Muribaculaceae and
Bacteroides) and increasing Ruminococcus, Oscillospira, Dorea and
the Lachnospiraceae family [29,30]. Consistent with previous studies,
this microbial composition can be induced by either obesogenic diets
or genetic mutations that lead to insulin resistance, inflammation and
excessive weight gain [31e34]. Our results showed that the gut
microbiota of both the HD and HDþ Bar groups markedly differed from
the control ND, indicating that diet drives gut microbiota community
structures. The HD diet was characterized by high fat and high simple
sugars (sucrose), while the ND diet mice had high complex poly-
saccharides (corn starch and maltodextrin), which might have
explained the higher level of saccharolytic fermentative gut bacteria,an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
Figure 3: PCoA showing differences in beta-diversity at T22 (BrayeCurtis dissimilarity index). The relative abundance in the 3 dietary groups at the phylum (A) and genus (B)
levels.
Original Articlesuch as Bacteroides and Ruminococcus, in the ND groups compared to
the HD. As previously documented [2], the mechanisms linking gut
microbiota dysbiosis to metabolic diseases include enhanced energy
harvesting from the diet, dysregulation of incretin signaling, metabolic
endotoxemia and chronic systemic inflammation. Whether these
mechanisms operate either in isolation or synergistically remains to be
determined as does whether microbiota dysregulation is a conse-
quence of metabolic disease or plays an etiological role in disease
onset. Cytokine signaling via JAKs plays an important role in the
pathogenesis of metabolic diseases as recently documented by both6 MOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier Gclinical and basic science research studies [6]. Following selective
binding of cognate ligands, several receptors can recruit JAK proteins,
leading to their dimerization and activation through autophosphor-
ylation. Recent studies based on tissue-specific KO mice pointed out
the essential role of the JAK-STAT cascade, mainly the JAK2 pathway,
in the peripheral metabolic organs, including the adipose tissue, liver,
skeletal muscle and pancreas. For instance, JAK2 deficiency in either
hepatocytes, macrophages or adipocytes confers resistance to diet-
induced metabolic stress and protects against HD-induced meta-
flammation and insulin resistance [12e14]. In contrast, loss of JAK3 inmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 4: Effects of dietary manipulation and baricitinib administration on the insulin signaling pathway. Western blotting analysis showing phosphorylation of Ser307 on IRS-1 in
the liver (A) and skeletal muscle (B), Ser473 on AKT in the liver (C) and skeletal muscle (D), and Ser9 on GSK-3b in the liver (E) and skeletal muscle (F) normalized to the related total
forms. All of the data are expressed as mean  SEM for n ¼ 6 per group. * p<0.05 vs ND and p< 0.05 vs HD.mice results in significant body weight increase, associated with
impaired glycemic homeostasis, hyperinsulinemia and early symptoms
of liver steatosis [11]. The JAK3 KO mice were more prone to devel-
oping high-fat induced metabolic syndrome than the control mice.
Although these findings collectively demonstrate that activation of the
JAK2 pathway does indeed occur in T2DM and may play a role in its
pathogenesis, its potential as a pharmacological target for drug therapy
of diet-induced metabolic derangements has been poorly investigated.
In this study, we demonstrated for the first time that the chronic
administration of baricitinib, an oral JAK1/2 inhibitor approved for the
treatment of rheumatoid arthritis, protects against the deleteriousMOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comeffects of chronic high-fat high-sugar feeding. While the weight gain
induced by HD was extremely rapid, more than 8 weeks of baricitinib
administration were needed to detect a significant reduction, pre-
sumably because baricitinib treatment started after the HD mice had
already developed obesity and insulin resistance (reversal study).
Despite the observed changes in body weight gain induced by bar-
icitinib, the HD and HD þ Bar mice did not differ in gut microbiota
composition, demonstrating the lack of direct local effects on gut
bacteria when baricitinib is administered orally. These findings further
support the theory that microbiota is involved, together with host
physiological changes induced by the obesogenic diet, in triggeringan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Figure 5: MRI analysis of the quadriceps muscle (A, B, C, D, E and F). Effects of HD and baricitinib administration on fat deposition in the skeletal muscle (G) and skeletal muscle
triglyceride levels (H). All of the data are expressed as mean  SEM for n ¼ 6 per group. *p< 0.05 vs ND and p< 0.05 vs HD.
Original Article
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Figure 6: Effects of HD and baricitinib administration on the kidneys. Acid-Schiff positive staining within the glomeruli (an indicator of mesangial expansion) (A, B and C) and
histological analysis of kidney sections (D, Eand F). Bowman’s capsule area (G), glomerular area (H), urinary albumin creatinine ratios (ACR; I), and expression level of cyclin kinase
inhibitor (p21, L) were evaluated in the kidneys of the mice exposed to ND or HD in the absence or presence of baricitinib (10 mg/kg die, p.o.). Values are mean  SEM for n ¼ 6
per group. *p<0.05 vs ND and p<0.05 vs HD.inflammation. However, recent evidence suggests that short-chain
fatty acids (SCFAs) generated by gut microbiota have a wide range
of functions from immune regulation to metabolism in a variety of
tissues and organs and therefore may directly or indirectly regulate
physiological and pathological processes in relation to obesity [35,36].
SCFAs have been demonstrated to participate in the mechanisms of
insulin secretion from the pancreatic b cells and the release of peptide
hormones that control appetite [37]. Thus, the lack of data on fecal
content of SCFAs does not allow us to exclude that the beneficial ef-
fects of baricitinib are due (at least in part) to potential drug interactions
with particular bacterial metabolites that may trigger regulatoryMOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.commetabolic cascades. In this study we mainly focused on the potential
drug effects on target organs and tissues of diet-induced metabolic
derangements. We demonstrated that baricitinib protects against the
deleterious effects of HD by inhibiting the JAK-STAT pathway in the
skeletal muscle, which exerts a key role in the regulation of glucose
homeostasis. Among the best characterized activators of JAK signaling
in the context of metabolic disorders, certain adipokines, including
leptin and resistin, are known to be involved in the pathogenesis of
insulin resistance [38,39]. The increase in their systemic concentra-
tions evoked by chronic exposure to an hypercaloric diet, as confirmed
herein, may contribute to the over-activation of JAK2 in both thean open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 9
Figure 7: Baricitinib attenuates the HD-induced JAK-STAT pathway. Western blotting analysis for phosphorylation of Tyr 1007/1008 JAK1/2 in the skeletal muscle (A) and kidneys (B)
and normalized to total JAK1/2 and for phosphorylation of Tyr 690 on STAT2 in the skeletal muscle (C) and kidneys (D) and normalized to total STAT2. All of the data are expressed
as mean  SEM for n ¼ 6 per group. *p< 0.05 vs ND and p< 0.05 vs HD.
Original Articleskeletal muscle and kidneys of the HD mice. When activated, JAK
phosphorylates STAT proteins, leading to their activation. Activated
STAT proteins can dimerize and translocate to the nucleus where they
regulate gene transcription, including cytokines production. Clinical
data showed an increased phosphorylation of JAK2 and STAT in
skeletal muscle biopsies from patients with T2DM and correlate with
measures of insulin resistance [40,41]. In this study, we confirmed that
HD does indeed drive the phosphorylation of JAK2 and STAT and re-
ported that the JAK1/2 inhibitor baricitinib attenuated the phosphory-
lation of both JAK2 and STAT in mice with an HD. These effects of
baricitinib were associated with a significant reduction in the plasma
concentrations of the JAK-STAT dependent cytokines IL-1b, TNF-a,
and IFN-g, whose role in obesity and insulin resistance has been
widely documented. In contrast, the anti-inflammatory cytokine IL-10
was upregulated following baricitinib exposure. We also documented a
significant increase in IL-6 concentrations following baricitinib
administration, consistent with a previous study showing that IL6-
deficient mice fed HD develop significant hepatosteatosis and insulin
resistance [42]. In fact, IL-6 is not a classical pro-inflammatory cyto-
kine and may exert several anti-inflammatory actions, including10 MOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier Gdownregulation of IFN-g, IL-1b, and TNF-a [43]. Treatment of the HD
mice with baricitinib also resulted in an increase in the plasma levels of
GIP and ghrelin, both of which are involved in glucose homeostasis
conferring protective effects for metabolic dysfunctions. In fact, beyond
its insulinotropic effects in the pancreas, GIP has been demonstrated to
exert important biological actions, including regulation of fat meta-
bolism, with a key role in modulating lipid storage in adipose tissue
[44]. Ghrelin signaling has been demonstrated to be another key
mediator linking nutrient-sensing signals with adipose inflammation
and insulin resistance. Ablation of ghrelin has been reported to worsen
diet-induced obesity, insulin resistance and adipose inflammation [45].
Our study provided the first evidence that the improved glucose
tolerance evoked by baricitinib administration in HD is, at least
partially, mediated by enhancing the insulin-related signaling
pathway in both the liver and skeletal muscle. The IRS-1/AKT/GSK-
3b pathway is a crucial regulator of glucose transportation, glycogen
synthesis and glycolysis [46]. The defects in insulin signaling
observed in the liver and skeletal muscle of the HD fed mice were
restored by pharmacological inhibition of JAK activity. Our data are
agree with previously published papers reporting a cross-talkmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 8: Plasma concentration of inflammatory cytokines Il-1b (A), TNF-a (B), IFN (C), IL-6 (D), and IL-10 (E). All of the data are expressed as mean  SEM for n ¼ 15 per group.
*p<0.05 vs ND and p<0.05 vs HD.between the insulin and JAK signaling cascades [47e49]. In
response to the administration of physiological concentrations of
insulin in rats, JAK2 associates with the insulin receptor and is then
phosphorylated in insulin-sensitive tissues [50]. Interestingly, JAK2
over-activation has been demonstrated to contribute to modulating
AKT phosphorylation and glucose uptake in models of insulin resis-
tance, whereas JAK2 knockdown in L6 myotubes alleviated insulin
resistance by interfering with the negative regulation of AKT phos-
phorylation and activity [51]. Overall, our results, in line with previ-
ously published data, demonstrated that the activation of JAK2
signaling may directly modulate the AKT pathway, thus affecting a
crucial pathogenic mechanism responsible for the development of
insulin resistance. As documented in patients with rare molecular
defects in the insulin signaling pathway [52], metabolic dyslipidemia
is the result of selective post-receptor hepatic insulin resistance.
Thus, we speculate that the preservation of insulin sensitivity may
also account for improved systemic lipid profiles and the decrease inMOLECULAR METABOLISM 39 (2020) 101009  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comthe deposition of intramuscular and perimuscular fat in the quadri-
ceps muscle of the HD mice treated with baricitinib. Unfortunately,
the lack of data on hepatic lipid levels does not allow us to conclude
that the drug’s beneficial effects on lipid profiles can be extended to
the liver itself. We also documented significant inhibition of the JAK2-
STAT2 pathway in the kidneys of the HD mice treated with baricitinib.
Podocyte-specific JAK2 overexpression worsens diabetic kidney
disease in mice [53]. This effect was associated with a significant
reduction in HD-induced renal injury (histology) and proteinuria. In
line with the reduction in proteinuria afforded by baricitinib, we
recorded significant prevention of the expansion of mesangial cells
and glomerular hypertrophy, both of which are hallmarks of diabetic
nephropathy. These effects were due, at least in part, to baricitinib-
induced reduction in cellular senescence as documented by the
significant reduction in renal expression of the cyclin kinase inhibitor
p21WAF1/CIP1 (p21). Hyperglycemia is known to evoke kidney cell
senescence through a p21-dependent pathway. More specifically,an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 11
Original Articlehigh glucose via the JAK2 pathway enhances the expression of p21,
which leads to cell cycle arrest in the G0/G1 phase and increased
expression of extracellular matrix proteins such as fibronectin and
type IV collagen and cellular hypertrophy of LLC-PK1 cells [54]. Thus,
the reduced expression of p21 recorded in the kidneys of the HD mice
exposed to baricitinib may be the direct consequence of JAK-STAT
inhibition, that, along with the improvement in insulin sensitivity
and plasma glucose levels, may contribute in direct and indirect
manners to reducing mesangial cell expansion and proteinuria.
Notably, these findings were consistent with a recently published
phase 2 randomized controlled clinical trial that tested the efficacy of
baricitinib in participants at a high risk of progression of diabetic
kidney disease, demonstrating significant reductions in ACR over 24
weeks with baricitinib treatment [15]. We speculate that the cross-
talk mechanism of action investigated contributed, at least in part,
to reaching the primary trial endpoint.
5. CONCLUSION
In conclusion, our results support the view that activation of the JAK2-
STAT2 pathway drives the development of obesity, insulin resistance,
associated end-organ injury and, most notably, highlights the potential
repurposing of JAK inhibitors already approved for rheumatoid arthritis
as promising treatment options in the clinical context of metabolic
diseases. In fact, the use of the JAK 1/2 inhibitor baricitinib, which was
administered for the last 16 weeks of the 22-week dietary manipu-
lation, exerted multi-organ protection against the deleterious effects of
HD exposure. Interestingly, targeting metaflammation by inhibiting JAK
signaling by orally administered small molecules such as baricitinib
might offer several advantages compared with a therapeutic strategy
centered on targeting cytokines with biologics, including better phar-
macokinetics and cost effectiveness, fewer immunosuppressive ef-
fects and wider simultaneous targeting of multiple pathogenic
pathways, making them very attractive and potentially suitable for drug
repurposing.
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